Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells.
Erratum to: Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination.
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Multiple Sclerosis.
Headache in relapse and remission phases of multiple sclerosis: A case-control study.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Mitoxantrone: benefits and risks in multiple sclerosis patients.
Extavia Prescribing Information
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
A map of the human neocortex showing the estimated overall myelin content of the individual architectonic areas based on the studies of Adolf Hopf.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Role of regulatory b cells in neuroimmunologic disorders.
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of masitinib in the treatment of pancreatic cancer
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
Myelin Gordon Research Conference
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Copaxone
SoCal Symposium on Glial-Neuronal Interactions in Health & Disease
Long-term effectiveness of glatiramer acetate in clinical practice conditions.
National MS Society: Ralph I. Straus Award
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.

Pages